Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Nutrients ; 14(17)2022 Aug 30.
Article in English | MEDLINE | ID: mdl-36079825

ABSTRACT

Maternal vitamin A (VA) supplementation in risk areas for Vitamin A deficiency (VAD) was launched to improve the level of this nutrient in nursing mothers and in their breast milk. This longitudinal and randomized study aimed to evaluate the levels of retinol in breast milk after supplementation with VA in varying amounts (200,000 IU or 400,000 IU) and different postpartum intervals. Women were distributed into four intervention groups and given a single 200,000 IU postnatal dosage of VA at time 0 h (postnatal morning) (G200 0H); a single 200,000 IU dosage of VA in week four (G200 4W); 200,000 IU of VA at time 0 h + 200,000 IU of VA 24 h after the first supplementation (G400 24H); and 200,000 IU of VA at time 0 h + 200,000 IU of VA one week after the first supplementation (G400 1W). Breast milk samples were collected over a 12-week period (0 h, 24 h and 1, 4, 12 weeks post-natal). Retinol levels were determined by high-performance liquid chromatography. The Generalized Estimated Equation (GEE) assessed the different retinol levels. The G200 (0H), G400 (24H), and G400 (1W) groups presented higher retinol levels at 24 h than the G200 (4W) group (p < 0.001). The retinol levels of all groups were similar at times 1, 4 and 12 weeks after delivery (p > 0.05). Maternal VA supplementation increased retinol levels in the colostrum. Different supplementation dosages or postpartum administration times did not result in added benefit to retinol levels in mature breast milk.


Subject(s)
Milk, Human , Vitamin A Deficiency , Dietary Supplements/analysis , Female , Humans , Milk, Human/chemistry , Postpartum Period , Vitamin A , Vitamin A Deficiency/prevention & control
2.
Toxicon ; 45(4): 421-9, 2005 Mar 15.
Article in English | MEDLINE | ID: mdl-15733563

ABSTRACT

Envenomation by Loxosceles spiders causes two main clinical manifestations: cutaneous and systemic loxoscelism. The factors contributing to the severity of loxoscelism are not fully understood. We have analysed biochemical and toxicity variations in venom of L. laeta and L. intermedia, with the aim to find a correlation with the seriousness of loxoscelism. Differences in expression of proteins, glycoproteins and sphingomyelinase activity were observed between venom from male and female spiders and between venom from the two species. These differences were reflected in the toxicity of the venoms including the capacity to induce complement-dependent haemolysis, dermonecrosis and lethality. Comparative analysis of gender and species, showed that these biological activities were more prominent in venom from female spiders, especially from L. laeta. Antiserum raised against venom from females L. laeta spiders had the highest efficacy in neutralizing venoms of males and females of both species. These results indicate that the severity of loxoscelism depends, at least partially, on the species and sex of the spider and suggest that for accidents involving L. laeta an specific serum therapy is necessary. Furthermore, it emphasizes the efficacy of the antiserum produced against L. laeta female venom in neutralizing Loxosceles venoms from different species and gender.


Subject(s)
Antivenins/metabolism , Skin/pathology , Spider Bites/metabolism , Spider Venoms/chemistry , Spiders/chemistry , Analysis of Variance , Animals , Antivenins/therapeutic use , Blotting, Western , Electrophoresis, Polyacrylamide Gel , Erythrocytes/drug effects , Female , Flow Cytometry , Hemolysis/drug effects , Humans , Lethal Dose 50 , Male , Mice , Mice, Inbred BALB C , Necrosis/chemically induced , Sex Factors , Species Specificity , Sphingomyelin Phosphodiesterase/metabolism , Spider Bites/chemically induced , Spider Bites/drug therapy , Spider Venoms/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL
...